Halbert Hargrove Global Advisors, LLC Celldex Therapeutics, Inc. Transaction History
Halbert Hargrove Global Advisors, LLC
- $2.02 Billion
- Q3 2025
A detailed history of Halbert Hargrove Global Advisors, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Halbert Hargrove Global Advisors, LLC holds 78 shares of CLDX stock, worth $2,158. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78Holding current value
$2,158% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
201Shares Held
68.3MCall Options Held
219KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$169 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$145 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$130 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$109 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$106 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.29B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...